(Q35984198)

English

Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model (English)

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

1 reference

based on heuristic

inferred from title

author name string

Jyothi Thyagabhavan Mony

1

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Lixin Zhang

2

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Tianzhou Ma

3

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Shannon Grabosch

4

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Tejas S Tirodkar

5

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Joan Brozick

6

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

George Tseng

7

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Esther Elishaev

8

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Robert P Edwards

9

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Xin Huang

10

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Anda M Vlad

11

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

publication date

22 May 2015

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

64

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

9

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

1095-1108

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

https://scigraph.springernature.com/pub.10.1007/s00262-015-1712-6

0 references

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

Immune modulation for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

Immunologic and clinical effects of targeting PD-1 in lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

"Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

Exploiting the curative potential of adoptive T-cell therapy for cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

Immune modulation in cancer with antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

Single-cell clones of liver cancer stem cells have the potential of differentiating into different types of tumor cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

Epithelial ovarian cancer experimental models.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

Nivolumab plus ipilimumab in advanced melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

MUC1 immunotherapy is here to stay

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

Immunobiology of human mucin 1 in a preclinical ovarian tumor model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

Immuno-oncology: understanding the function and dysfunction of the immune system in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

Adoptive immunotherapy for cancer: harnessing the T cell response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

Targeting natural killer cells and natural killer T cells in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

Knockdown of interferon-induced transmembrane protein 1 (IFITM1) inhibits proliferation, migration, and invasion of glioma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

PD-1 and its ligands in tolerance and immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

Anti-tumor antibodies in ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

Development of a syngeneic mouse model for events related to ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

2 October 2017

A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

11 July 2018

B cell-regulated immune responses in tumor models and cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

24 September 2018

Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

24 September 2018

Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4545381

24 September 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1712-6

21 January 2018

The emerging role of large immunophilin FK506 binding protein 51 in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1712-6

21 January 2018

PD-L1 is induced in hepatocytes by viral infection and by interferon-α and -γ and mediates T cell apoptosis

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1712-6

21 January 2018

Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25998800

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25998800

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00262-015-1712-6

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35984198&oldid=1641988324"